Quarterly ResultMay 12, 2026, 05:02 PM
SANUWAVE Q1 Revenue $9.6M, Operating Loss $1.1M
AI Summary
SANUWAVE Health, Inc. reported Q1 2026 revenues of $9.6 million, a 3.1% increase year-over-year, marking the highest Q1 revenues in company history. Despite the revenue growth, the company posted a GAAP operating loss of $1.1 million, a significant swing from an operating income of $0.6 million in Q1 2025, and gross margin declined to 77.3%. However, net loss improved to $1.4 million from $6.1 million in the prior year, largely due to non-cash items. The CEO noted a market recovery starting in February and expressed optimism, with the company providing positive revenue guidance for Q2 and reiterating full-year 2026 guidance.
Key Highlights
- Q1 2026 revenues were $9.6 million, up 3.1% from $9.3 million in Q1 2025.
- Q1 2026 GAAP Operating Loss was $1.1 million, a swing from $0.6 million operating income in Q1 2025.
- Q1 2026 gross margin was 77.3%, down from 79.0% in Q1 2025.
- Q1 2026 net loss was $1.4 million, an improvement from $6.1 million in Q1 2025.
- Ultramist® consumables revenue increased by 15.0% to $6.7 million in Q1 2026.
- Adjusted EBITDA for Q1 2026 was $1.1 million, down from $2.3 million in Q1 2025.
- Company forecasts Q2 2026 revenue of $11.1 to $11.6 million (10-15% increase).
- Full year 2026 revenue guidance reiterated at $51.0-$55.0 million (16-25% increase).
Price Impact
More from SNWV